Daniel Kantor
YOU?
Author Swipe
View article: Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications
Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications Open
Objective To assess the prevalence of multiple sclerosis (MS) activity, as well as neurologic and non-neurologic immune-related adverse events (irAEs) in persons with MS (pwMS) treated with immune checkpoint inhibitors (ICIs) for cancer. B…
View article: Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States Open
Treatment with ozanimod was associated with substantial reductions in annual drug costs and total MS-related healthcare costs to avoid relapses compared with other DMTs. In the fixed-budget analysis, ozanimod demonstrated a favorable cost-…
View article: Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study Open
Baclofen, a racemic γ-aminobutyric acid B receptor agonist, is commonly used for the management of multiple sclerosis–related spasticity but is associated with frequent dosing and poor tolerability. Arbaclofen, the active R-enantiomer of b…
View article: Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial Open
Baclofen, a racemic GABA-B (GABAB) receptor agonist, is commonly used for the management of multiple sclerosis-related spasticity but is associated with frequent dosing and poor tolerability. Arbaclofen, the active R-enantiomer of baclofen…
View article: Digital Scientific Platform for Independent Content in Neurology: Rigorous Quality Guideline Development and Implementation
Digital Scientific Platform for Independent Content in Neurology: Rigorous Quality Guideline Development and Implementation Open
Background Digital communication has emerged as a major source of scientific and medical information for health care professionals. There is a need to set up an effective and reliable methodology to assess and monitor the quality of conten…
View article: Effectiveness of alternative dose fingolimod for multiple sclerosis
Effectiveness of alternative dose fingolimod for multiple sclerosis Open
This study provides Class IV evidence that for patients with MS on daily dose fingolimod with adverse events, alternate dose fingolimod is associated with disease activity similar to daily dose fingolimod.
View article: Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine
Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine Open
The above summary slide and author video represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” …
View article: Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine
Perspectives from the Patient and the Healthcare Professional in Multiple Sclerosis: Social Media and Participatory Medicine Open
When faced with a diagnosis of multiple sclerosis (MS), patients often turn to the Internet and social media to find support groups, read about the experiences of other people affected by MS and seek their advice, and research their condit…
View article: Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis
Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis Open
The multiple sclerosis (MS) treatment landscape in the United States has changed dramatically over the past decade. While many disease-modifying therapies (DMTs) have been approved by the US Food and Drug Administration (FDA) for the treat…
View article: Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate Open
In summary, this comprehensive approach across different biological and immunological pathways modulated by glatiramer acetate consistently supported the biological and immunological equivalence of Glatopa and Copaxone.
View article: Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analyses
Comparative clinical efficacy of alemtuzumab and ocrelizumab in patients with relapsing-remitting multiple sclerosis: Number needed to treat analyses Open
[Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Boster, A.] OhioHealth, Columbus, OH USA. [Alroughani, R.] Amiri Hosp, Sharq, Kuwait. [Berkovich, R.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA. [Izquierdo, G.] Virgen M…